Services
Online Inquiry
For research use only. Not intended for any clinical use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Non-Human Primate (NHP) Immunotoxicity & Cytokine Release Assay Service
Are you currently facing challenges in assessing the immunotoxic potential of novel biotherapeutics, particularly when dealing with complex immune-related diseases and species-specific cross-reactivity? Our NHP Immunotoxicity & Cytokine Release Assay (CRA) services provide a rapid and comprehensive means to evaluate drug safety and gain crucial mechanistic insights through advanced in vitro assays leveraging our extensive NHP resources and expanded analyte panels. Accelerate Your Drug Development with Precision Immunotoxicity Analysis!
Overview of NHP Immunotoxicity & CRAs
What Our Service Is
Our NHP Immunotoxicity & CRA services are a suite of specialized in vitro assays designed to assess the potential for a therapeutic to elicit an undesirable immune response. We use NHP immune cells, such as peripheral blood mononuclear cells (PBMCs), as a highly translationally relevant model. This service is essential for:
- Cytokine Release Syndrome (CRS) Risk Assessment: Quickly and cost-effectively evaluating a drug's potential to trigger an uncontrolled, systemic inflammatory response.
- Immunomodulatory Drug Evaluation: Understanding the intended and unintended effects of therapeutics designed to enhance or suppress immune function.
- Mechanistic Insights: Providing detailed data on the specific signaling pathways and cell populations a therapeutic engages, which is critical for understanding its mechanism of action.
Why Choose Us?
Immunotoxicity evaluation in preclinical development is complicated by species-specific cross-reactivity and the high cost of in vivo studies. Using rodents often fails to predict human responses, especially for biologics like monoclonal antibodies (mAbs) which may only cross-react with NHPs. Creative Biolabs addresses these critical pain points by providing an advanced in vitro platform that bridges the gap. By leveraging our deep expertise, we help you overcome the challenges of inter-animal variability and obtain meaningful data to guide your development program. Our services provide a cost-effective, rapid, and predictive alternative to traditional in vivo testing, giving you the confidence to move forward.
Distributed under Unsplash License, from Unsplash.
Key Benefits of Our Service
At Creative Biolabs, we have honed our NHP immunotoxicity assessment services to provide unparalleled precision and insight. Our key advantages are built on a foundation of scientific rigor and client-focused delivery.
- Exceptional Response Speed: Our streamlined workflows and dedicated NHP resources allow us to provide rapid turnaround times, accelerating your drug development timelines and allowing for quicker go/no-go decisions.
- Extensive NHP Resources: We maintain access to a consistent supply of healthy, well-characterized NHPs, ensuring the availability of high-quality, viable immune cells for your assays. Our experience with key species like cynomolgus macaques minimizes inter-animal variability for more reliable results.
- Complete Customization: We recognize that every therapeutic is unique. Our scientific team works with you to design a custom assay tailored to your specific molecule, mechanism of action, and research questions. We can adapt stimulation conditions, co-culture systems, and analyte panels to meet your project's precise needs.
How Creative Biolabs' Safety Assays Can Assist Your Project?
Our process is structured to be transparent and efficient, guiding you from initial inquiry to final report. The typical timeframe for this service ranges from 2 to 4 weeks, depending on the complexity and scope of the project.
01
Required Starting Materials
02
Consultation & Study Design
03
NHP Sample Procurement
04
Assay Execution
05
Data Acquisition
06
Analysis & Interpretation
Key Deliverables
All Creative Biolabs projects conclude with a complete package of deliverables to ensure full transparency and usability.
- Comprehensive Lab Report: A detailed document outlining the study design, methods, results, and expert scientific conclusions.
- Raw Data Files: All original data files, including multiplex assay output, flow cytometry FCS files, and statistical analysis outputs.
- Model Annotations: Detailed notes on the specific NHP models and donors used, providing full traceability and context.
- Statistical Analysis: An independent statistical analysis report validating the significance of the findings.
Capabilities & Partnerships
Service-Specific Data
- Annual Sample Size: Over 50,000 samples analyzed per year.
- Turnaround Time (TAT): Typical turnaround of 2 weeks for bioanalytical results.
- Study Pass Rate: 99%+ success rate in meeting study endpoints.
Our Valued Partners
Frequently Asked Questions
Q: What are the key advantages of using NHP PBMCs for immunotoxicity assays instead of human cells?
A: While human PBMCs are valuable, NHP cells are often a better model for therapeutics that are species-specific, particularly monoclonal antibodies. They provide a more reliable and predictive preclinical model, helping you gain crucial insights before moving to in vivo studies.
Q: How do you handle the high inter-animal variability in NHP studies?
A: We address this through rigorous study design, using a sufficient number of individual donors, and by employing advanced statistical analysis to identify significant trends. We also work with specific NHP populations with more consistent genetic backgrounds to minimize variability. If you have concerns, our team can discuss specific strategies to ensure data reliability for your project.
Q: What makes an expanded analyte panel so important?
A: Traditional CRAs focus on a limited set of cytokines, primarily for assessing Cytokine Release Syndrome. An expanded panel, as demonstrated in published data, provides broader safety data and reveals the subtle, but critical, mechanistic insights into your drug's immunomodulatory effects that would otherwise be missed. This helps you anticipate and manage potential toxicities early.
Q: Can you customize the assay to my specific project needs?
A: Absolutely. Our approach is highly collaborative. We understand that your therapeutic has unique characteristics. Our scientists will work with you to choose the optimal stimulant (polyclonal, antigen-specific, or a combination), cell type, and analyte panel to ensure the assay is perfectly suited to your project.
Q: What if my drug is designed to suppress the immune system? Are CRAs still useful?
A: Yes, absolutely. For immunosuppressive drugs, we can use polyclonal activators or viral antigens to intentionally activate the immune system and then measure your drug's ability to inhibit that response. This provides a direct measure of efficacy and helps identify potential risks of over-immunosuppression.
Contact Us
Creative Biolabs is a leader in preclinical immunotoxicity assessment, providing a powerful platform for evaluating novel therapeutics. Our NHP Immunotoxicity & CRA services offer a precise, rapid, and cost-effective solution for gaining critical safety data and mechanistic insights. To learn more about how our NHP Immunotoxicity & Cytokine Release Assay services can support your project and to get a quote, please reach out to our team of experts.